Neuphoria Therapeutics Inc (NEUP) Cash Flow Statement
Where NEUP’s cash came from and went, FY2026
June 30, 2026 · U.S. dollars- Cash from operations
- −$12.35B −16,095.4% vs FY2025
- Capital expenditures
- $4 0.0% of revenue
- Free cash flow
- −$12.35B −1,052,073.1% margin
- Returned to shareholders
- —
- Change in cash
- $5.58B cash at year-end $19.87B
Drawn to scale: where the cash came from and how it was used. Hover for values.
NEUP operating cash flow, capex and free cash flow
NEUP cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$1.4MFY2017 | −$12.35BFY2026 | — | |
| Capital expenditures | $247,511FY2017 | $4FY2026 | −70.7%/yr | |
| Free cash flow | −$1.7MFY2017 | −$12.35BFY2026 | — | |
| Free cash flow margin | −6.2%FY2017 | −1,052,073.1%FY2026 | −1,052,066.9 pts | |
| Stock-based compensation | $38,035FY2020 | $351.6MFY2026 | +358.1%/yr | |
| Share buybacks (net) | $420,369FY2019 | $415,479FY2021 | −0.6%/yr | |
| Capex / revenue | 0.9%FY2017 | 0.0%FY2026 | −0.9 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
NEUP cash flow by activity
NEUP net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
NEUP cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$13.45B | −$369.6M | −$15.5M | −$14.4M | −$21.8M | −$6.5M | −$4.9M | −$10.4M | — | — |
| Depreciation & amortization | $662,955 | $662,890 | $662,991 | $970,679 | $1.1M | $1.3M | $1.7M | $1.4M | — | — |
| Stock-based compensation | $351.6M | $163.8M | $814,808 | $1.3M | $2.8M | $983,011 | $38,035 | — | — | — |
| Change in working capital | −$4.1M | −$496,826 | $1.5M | $3.1M | −$5.6M | $1.2M | $2.8M | −$480,020 | $63,958 | $970,523 |
| Other non-cash items | $750.6M | $282.9M | −$2.1M | −$863,425 | $1.7M | −$2.6M | −$2.3M | −$1.5M | — | — |
| Cash from operating activities | −$12.35B | $77.2M | −$14.7M | −$9.8M | −$21.8M | −$5.7M | −$2.7M | −$10.9M | −$15.0M | −$1.4M |
| Investing activities | ||||||||||
| Capital expenditures | −$4 | $0 | $0 | −$0 | −$1,543 | −$1,102 | −$5,293 | −$69,282 | −$358,109 | −$247,511 |
| Investments (net) | — | — | — | $317,415 | $427,675 | −$60,262 | — | — | — | — |
| Acquisitions & other investing | — | — | — | −$1 | $195,505 | $1,103 | −$128,785 | $207,705 | $417,791 | $1.2M |
| Cash from investing activities | — | — | — | $317,414 | $621,637 | −$60,261 | −$134,078 | $138,423 | $59,682 | $953,940 |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | −$415,479 | −$48,228 | −$420,369 | — | — |
| Net borrowing (repayment) | — | — | — | −$105,936 | −$119,846 | −$8.9M | — | — | — | — |
| Shares issued | $17.9M | $0 | $10.1M | $3.9M | $22.6M | $32.9M | $0 | $0 | $0 | $0 |
| Other financing | $17.90B | $1.53B | $5.0M | $2.1M | $4.5M | $103,313 | −$3.6M | $3.5M | $1.9M | −$2.1M |
| Cash from financing activities | $17.92B | $1.53B | $15.1M | $5.8M | $27.0M | $23.7M | −$3.7M | $3.0M | $1.9M | −$2.1M |
| Summary | ||||||||||
| Net change in cash | $5.58B | $1.60B | $504,991 | −$15.0M | $5.1M | $18.0M | −$6.5M | −$7.7M | −$13.2M | −$2.6M |
| Cash at end of period | $19.87B | $14.29B | $12.7M | $8.1M | $33.6M | $21.4M | $3.1M | $9.8M | $18.3M | $42.9M |
| Free cash flow | −$12.35B | $77.2M | −$14.7M | −$9.8M | −$21.8M | −$5.7M | −$2.7M | −$11.0M | −$15.4M | −$1.7M |
| Free cash flow margin | −1,052,073.1% | 493.5% | — | — | −5,677.8% | −610.8% | −8,381.4% | −148.5% | −128.8% | −6.2% |
| Capex / revenue | 0.0% | 0.0% | — | — | 0.4% | 0.1% | 16.5% | 0.9% | 3.0% | 0.9% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$13.44B | −$505,063 | $1.9M | −$9.9M | −$378.1M | $11.3M | −$1.9M | −$804,787 | −$2.7M | −$4.3M | −$6.7M | −$8.5M |
| Depreciation & amortization | $165,679 | $165,695 | $165,789 | $165,792 | $662.4M | $165,431 | $166,121 | $165,713 | $165,685 | $255,175 | $242,820 | $259,120 |
| Stock-based compensation | $351.3M | $70,286 | $93,701 | $111,277 | $163.7M | $19,685 | $19,084 | $26,736 | $107,716 | $26,756 | $816,238 | $207,314 |
| Change in working capital | $98,090 | −$2.3M | −$5.1M | $1.4M | $1.4M | −$642,517 | −$328,158 | −$1.2M | $2.3M | −$1.7M | −$311,175 | $806,020 |
| Other non-cash items | $13.09B | −$1.3M | −$3.4M | $4.4M | −$375.7M | $648,692 | −$1.3M | −$2.6M | −$2.9M | $624,916 | $145,030 | $356,164 |
| Cash from operating activities | $1.2M | −$3.9M | −$6.4M | −$3.8M | $73.6M | $11.5M | −$3.4M | −$4.4M | −$3.0M | −$5.1M | −$5.8M | −$6.9M |
| Investing activities | ||||||||||||
| Capital expenditures | $0 | −$2 | $0 | −$2 | −$3 | $0 | −$1 | −$3 | $0 | $0 | $0 | $0 |
| Acquisitions & other investing | — | — | — | — | — | — | — | — | — | — | — | $187,409 |
| Cash from investing activities | — | — | — | — | — | — | — | — | — | — | — | $187,409 |
| Financing activities | ||||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | — | — | — | — | — | −$810,361 |
| Shares issued | $0 | $0 | $14.7M | $3.3M | $0 | $823,601 | $0 | $0 | $2.1M | $1.4M | $288,782 | $6.3M |
| Other financing | $109,953 | $698,948 | $0 | $0 | $701,490 | $338,900 | −$111,562 | −$227,338 | $5.0M | $1.3M | $8.0M | −$4.5M |
| Cash from financing activities | $109,953 | $698,948 | $14.7M | $3.3M | $701,490 | $1.2M | −$111,562 | −$227,338 | $7.1M | $2.7M | $8.2M | $956,675 |
| Summary | ||||||||||||
| Net change in cash | $424,876 | −$2.8M | $8.5M | −$560,488 | $14.27B | $12.7M | −$3.7M | −$4.5M | $4.2M | −$2.7M | $3.0M | −$6.2M |
| Cash at end of period | $19.87B | $19.4M | $22.3M | $13.7M | $14.29B | $17.1M | $4.4M | $8.2M | $12.7M | $13.1M | $15.0M | $12.8M |
| Free cash flow | −$12.34B | −$3.9M | −$6.4M | −$3.8M | $73.6M | $11.5M | −$3.4M | −$4.4M | −$3.0M | −$5.1M | −$5.8M | −$6.9M |
| Free cash flow margin | −1,050,917.6% | — | — | — | — | 76.4% | −506.7% | −44.1% | — | — | — | — |
| Capex / revenue | 0.0% | — | — | — | — | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Operating cash flow / net income | — | — | −3.45 | — | — | 1.02 | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
NEUP cash generation
In fiscal 2026 (ended June 30, 2026), Neuphoria Therapeutics generated -$12.4 billion of cash from operations (down 16,095.4%) and spent $0.0 million on capital expenditures, leaving free cash flow of -$12.4 billion, −1,052,073.1% of revenue. Cash and equivalents rose by $5.6 billion over the year.
Related: NEUP income statement, NEUP balance sheet. See the NEUP stock overview for the latest quote and news.
NEUP cash flow FAQ
What is Neuphoria Therapeutics's free cash flow?
Neuphoria Therapeutics's free cash flow was -$12.4 billion in fiscal 2026: -$12.4 billion of operating cash flow minus $0.0 million of capital expenditures It was $77.2 million a year earlier..
How much cash does Neuphoria Therapeutics generate from operations?
Neuphoria Therapeutics generated -$12.4 billion of cash from operating activities in fiscal 2026.
How much does Neuphoria Therapeutics spend on capital expenditures?
Neuphoria Therapeutics spent $0.0 million on capital expenditures in fiscal 2026, 0.0% of revenue.